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Phospholamban R14 Deletion Results
n Late-Onset, Mild, Hereditary Dilated Cardiomyopathy
egan M. DeWitt, BS,* Heather M. MacLeod, MS,* Betty Soliven, MD,†
lizabeth M. McNally, MD, PHD*‡
hicago, Illinois
OBJECTIVES The purpose of this research was to determine the phenotypic spectrum associated with
phospholamban gene (PLN) mutations.
BACKGROUND Inheritance contributes to the development of dilated cardiomyopathy. Mutations in the gene
encoding PLN have been associated with dilated cardiomyopathy characterized by early onset
and the presence of lethal ventricular arrhythmias.
METHODS We screened a cohort of 260 unrelated dilated cardiomyopathy patients from a tertiary care
referral center for mutations in the PLN gene.
RESULTS Family history of cardiomyopathy was present in approximately one-half the individuals in
this cohort. We identified 1 family with a deletion of arginine 14 in the PLN. Interestingly,
unlike other individuals reported with the identical PLN mutation, these individuals were not
diagnosed with dilated cardiomyopathy until their seventh decade when they were only mildly
symptomatic with congestive heart failure.
CONCLUSIONS The identical PLN mutation can be associated with both mild and severe forms of dilated
cardiomyopathy. Additionally, PLN mutations should be considered in late onset cardiomy-
opathy. (Genetics of Cardiovascular and Neuromuscular Disease; http://www.
clinicaltrials.gov/ct/show/NCT00138931?order1; NCT00138931) (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.0162006;48:1396–8) © 2006 by the American College of Cardiology Foundation
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Cilated cardiomyopathy (DCM) is inherited commonly as a
ominant disorder associated with a range of genetic defects
1). Despite genetic heterogeneity, abnormal calcium han-
ling is a hallmark of DCM (2). An increase in cytosolic
alcium or prolonged intervals of increased calcium pro-
uces cardiomyocyte dysfunction and predisposes to ar-
hythmias (3). The sarcoplasmic reticulum calcium ATPase
a (SERCA2a) mediates cyclic uptake of calcium from the
yoplasm into the sarcoplasmic reticulum; SERCA2a is
egulated, in part, by phospholamban, a small 52 amino acid
embrane-associated protein (4). With dephosphorylation,
hospholamban inhibits SERCA2a leading to prolongation
f increased cytosolic calcium. Phospholamban is phosphor-
lated by protein kinase A (PKA) leading to derepression, or
ctivation, of SERCA2a and an increase in removal of
ytosolic calcium during diastole.
Consistent with the importance of calcium handling to
ormal myocyte function, phospholamban gene (PLN)
utations have been found in inherited DCM (5,6). A
oint mutation in PLN, R9C, was found in a single large
amily with an average age of onset of 20 to 30 years and
udden death at an average of 25 (5). Transgenic mice
xpressing PLN R9C under the control of the alpha myosin
eavy chain gene promoter developed lethal cardiomyopa-
hy. The PLN R9C mutation sequesters PKA preventing
hosphorylation of normal phospholamban and enhanced
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ccepted July 10, 2006.nhibition of SERCA2a activity (5). A second mutation,
39X, was also reported linked to human DCM (6). In this
ase, when carried heterozygously, the L39X mutation
roduced an asymptomatic hypertrophic cardiomyopathy.
n the homozygous state, the L39X mutation was associated
ith early-onset, lethal, DCM. Most recently, a deletion of
14 in phospholamban (PLN R14del) was found in a large
amily with early-onset lethal DCM (7). This mutation was
lso shown to sequester PKA leading to a decrease in
hospholamban phosphorylation and SERCA2a inhibition.
We now screened a cohort of 260 DCM patients for
utations in the PLN. We found a single family with 2
ffected individuals. We independently identified these
atients as carrying the PLN R14del mutation. Strikingly,
he age of onset in these patients was in the seventh decade.
herefore, mutations in phospholamban can be associ-
ted with a variable phenotype including late-onset, mild
ardiomyopathy.
ETHODS
uman subjects. Criteria for inclusion included: 1) ejec-
ion fraction 45% or 2) left ventricular (LV) end diastolic
iameter 117% of the predicted value, and 3) absence of
ignificant epicardial coronary artery disease, and/or hyper-
ensive, systemic, pericardial, or congenital disease that
xplains the cause of DCM (8,9). Written and informed
onsent was obtained in accordance with the University of
hicago’s Institutional Review Board. Clinical data were
btained through evaluations performed at the University of
hicago Cardiology Clinics. Family history was ascertainedrom the patients by a certified genetic counselor, and
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roband to family member contact.
enetic analysis. Deoxyribonucleic acid was isolated from
hole blood using PureGene (Gentra Systems, Inc., Min-
eapolis, Minnesota) according to recommendations. Direct
equencing of polymer chain reaction products was com-
leted using cycle sequencing and compared with the
uman PLN sequence (GenBank Accession NM_002667).
ingle strand conformation polymorphism analysis was
erformed using MDE (FMC Corporation, Philadelphia,
ennsylvania) as described (10). Structural modeling was
erformed using Cn3D 4.1.
ESULTS
CM cohort. Of the 260 unrelated DCM subjects
creened, 35% of these had a strong family history of DCM
s defined by at least 1 relative with proven DCM. An
dditional 27% had a “suspicious” or moderately positive
amily history for DCM because of sudden death at a young
ge in a first-degree relative (female subjects 50 years of
ge, male subjects 45 years of age), and the circumstances
urrounding the death were suspicious for arrhythmia.
hirty-seven percent did not have a family history sugges-
ive of DCM and/or arrhythmias, and family history was
ot available for 1% of subjects.
linical and genetic results. We identified a single PLN
utation, R14del, in a 61-year-old Caucasian woman
Abbreviations and Acronyms
DCM  dilated cardiomyopathy
LV  left ventricle/ventricular
PLN  phospholamban gene
PLN R14del  deletion of R14 in phospholamban
PKA  protein kinase A
SERCA2a  sarcoplasmic reticulum calcium ATPase 2a
igure 1. Phospholamban gene R14del in dilated cardiomyopathy. (A) Pe
14del mutation. (B) Single-strand conformation change indicating the phospho
0 and 11 represent the proband and her brother, respectively.DCM-X1) initially evaluated in a muscular dystrophy
linic for a 25-year history of slowly progressive muscle
eakness. She noted leg pain, difficulty standing from a
itting position, and difficulty climbing stairs. Neurological
xam showed mild weakness in hip flexion and abduction
ith normal strength in other limb muscles. A quadriceps
keletal muscle biopsy showed no significant abnormalities
ith normal staining patterns for dystrophin, -sarcoglycan,
-sarcoglycan, -sarcoglycan, merosin, -dystroglycan,
-dystroglycan, and dysferlin. Her serum creatine kinase
as normal. An echocardiogram revealed severely impaired
V performance with an estimated ejection fraction of 20%,
-chamber dilatation, and impaired right ventricular func-
ion. Cardiac catheterization revealed no significant coro-
ary artery disease and an apical LV thrombus. At age 63,
he patient underwent prophylactic implantation of a defi-
rillator. The patient had 4 successful pregnancies in her
hird and fourth decades.
The proband’s family history was significant for her
rother (DCM-X2) who was found at age 70 to have an LV
jection fraction of 15% to 20% (Fig. 1). He also was found
o have the PLN R14del mutation. He was active with no
omplaints related to heart failure. During his evaluation, he
as noted to have atrial flutter and bradycardia and no
ignificant coronary artery disease. He received a single-
hamber atrial pacemaker that was upgraded to a dual-
hamber defibrillator at age 72 after a syncopal episode.
ther members of the family do not carry PLN R14del and
ave normal echocardiograms. The mutation was not de-
ected in 100 unrelated normal, ethnically matched control
ubjects.
ISCUSSION
he PLN mutation in this family falls within a conserved
omain of phospholamban (Fig. 2). It cannot be determined
hether R13 or R14 is deleted because the codon for each
with proband (*).  or  indicates the presence or absence of the PLNdigree
lamban gene R14 deletion mutation in the members of the pedigree. Lanes
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o partially disrupt the stability of the pentamer structure of
his 52 amino acid protein (7). Structural information on
he cytoplasmic region as a monomer predicts that the
egion containing these residues may change with local
nwinding upon phosphorylation (11). Nuclear magnetic
esonance structure of phospholamban in a lipid environ-
ent suggest an “L” shape for phospholamban where the
ytoplasmic domain is perpendicular to the membrane-
nserted domain (12).
The PLN R14del was recently associated with a lethal
orm of early-onset familial DCM (7). This severe pheno-
ype resembles the R9C mutation and displays a similar
henotype in a murine model (5,7). Based on these 2
eports, it has been suggested that PLN screening only be
ursued in families with early-onset DCM. We now report
family in which 2 individuals carry the identical PLN
14del, yet these individuals display a distinctively milder
ourse. Both mutation carriers were diagnosed late in life
ith asymptomatic DCM. Before diagnosis, both led nor-
igure 2. Consensus sequence of phospholamban gene residues 1 to 30.
hospholamban gene amino acid residues 13 and 14 are identical and are
onserved among species. The following protein sequences are aligned, and the
enBank Accession numbers are indicated as follows: human (NP_002658),
at (NP_073198), mouse (NP_075618), dog (NP_001003332), rabbit
CAA68730), pig (NP_999378), chicken (NP_990741), zebrafish
XM_701636.1), and puffer fish (CAG06667). The solution structure of the
ytoplasmic domain is shown on the left (11), and the NMR structure of
hospholamban in a lipid environment is shown on the right (12). The
ositioning of the R13/R14 residues is shown in yellow.al lives with no decrement in symptomatic cardiac func-ion. Interestingly, the proband reported skeletal muscle
eakness that was in a limb girdle distribution. Phospho-
amban is expressed in slow skeletal muscle and could be
ssociated with a skeletal muscle phenotype. These findings
uggest that PLN mutation screening should be more
roadly considered in individuals with DCM.
The finding of an identical mutation in PLN associated
ith both mild and severe forms of cardiomyopathy sug-
ests that other genetic loci may be present that modify the
utcome of PLN-mediated cardiomyopathy. Several studies
ave suggested that the level of phospholamban expression
s critical in mediating its effect (4). It is possible that the
utant allele of PLN is expressed at a lower level leading to
smaller pathogenic effect in these individuals. Alterna-
ively, mutations in genes outside of the PLN locus may
e present that lead to a less severe phenotype in these
ndividuals.
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